Dear Doctor Letter (Rote-Hand-Brief) on Tredaptive® (combination of niacin/laropiprant): Discontinuation of marketing
2013.01.22
Active substance: niacin, laropiprant
The pharmaceutical manufacturer is sending out information that due to new data available from a clinical trial the marketing of the medicinal product Tredaptive® has been discontinued and that therefore treatment with this medicinal product is to be terminated. The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) had previously issued a recommendation of suspension for the marketing authorisations concerned.
Download DHPC/Information letter , Download_VeroeffentlichtAm_EN